Medicare Enrolled

Dr. Kayvan Kamali, M.D.

Rheumatology · Longview, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
920 JUDSON RD, Longview, TX 75601
9032367020
In practice since 2005 (20 years)
NPI: 1013912856 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kamali from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kamali? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Kamali

Dr. Kayvan Kamali is a rheumatology in Longview, TX, with 20 years in practice. Based on federal Medicare data, Dr. Kamali performed 7,086 Medicare services across 1,518 unique beneficiaries.

Between the years covered by Open Payments, Dr. Kamali received a total of $35,771 from 43 pharmaceutical and/or device companies across 1672 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Kamali is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ Top 40% volume in TX$ $35,771 industry payments

Medicare Practice Summary

Medicare Utilization ↗
7,086
Medicare services
Top 40% in TX for rheumatology
1,518
Unique beneficiaries
$37
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~354 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Denosumab injection (Prolia/Xgeva)3,600$18$45
Office visit, established patient (30-39 min)1,621$83$166
Steroid injection (triamcinolone)779$1$30
Office visit, established patient (20-29 min)233$60$114
Bone density scan (DEXA)224$36$511
Drug injection, under skin or into muscle206$10$43
X-ray of entire middle and lower spine, 2-3 views87$45$255
New patient office visit, complex (60-74 min)84$147$346
Administration of chemotherapy into vein, 1 hour or less70$97$642
Joint injection, major joint58$52$246
Mri scan of arm without contrast40$166$1,858
Mri scan of arm joint without contrast39$84$2,109
Injection, methylprednisolone acetate, 40 mg26$6$30
Injection, methylprednisolone acetate, 80 mg19$9$40
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$35,771
Total received (2018-2024)
Avg $5,110/year across 7 years
Top 13% in TX for rheumatology
43
Companies
1,672
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$35,573 (99.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$199 (0.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$4,741
2023
$6,835
2022
$5,222
2021
$5,201
2020
$2,758
2019
$5,279
2018
$5,736

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$7,159
ABBVIE INC.
$5,998
AbbVie Inc.
$2,721
AbbVie, Inc.
$2,571
Lilly USA, LLC
$2,266
UCB, Inc.
$1,770
PFIZER INC.
$1,477
GlaxoSmithKline, LLC.
$1,450
Radius Health, Inc.
$1,438
Janssen Biotech, Inc.
$1,102
Novartis Pharmaceuticals Corporation
$1,102
GENZYME CORPORATION
$971
Aurinia Pharma U.S., Inc.
$959
AstraZeneca Pharmaceuticals LP
$901
E.R. Squibb & Sons, L.L.C.
$757
Celgene Corporation
$368
Daiichi Sankyo Inc.
$349
Horizon Therapeutics plc
$258
Fresenius Kabi USA, LLC
$236
Genentech USA, Inc.
$229
Boehringer Ingelheim Pharmaceuticals, Inc.
$220
Janssen Scientific Affairs, LLC
$220
Mallinckrodt Hospital Products Inc.
$189
Eisai Inc.
$118
Horizon Pharma plc
$113
Bioventus LLC
$103
Takeda Pharmaceuticals U.S.A., Inc.
$102
Alexion Pharmaceuticals, Inc.
$92
Collegium Pharmaceutical, Inc.
$91
Sandoz Inc.
$72
BioDelivery Sciences International, Inc.
$61
SANOFI-AVENTIS U.S. LLC
$44
Organon LLC
$41
Flexion Therapeutics, Inc.
$33
Forte Bio-Pharma LLC
$28
Antares Pharma, Inc.
$27
MEDAC PHARMA, INC.
$27
ANI Pharmaceuticals, Inc.
$26
EISAI INC.
$24
ASSERTIO THERAPEUTICS, Inc.
$19
Mylan Institutional Inc.
$17
Orthogenrx Inc.
$15
Organon Llc
$9
Top 3 companies account for 44.4% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · BELBUCA · BENLYSTA · BUNAVAIL 2.1 mg 30-count box · Belbuca · Bimzelx · COLOGUARD · COSENTYX · Cimzia · DUEXIS · Dayvigo · Durolane · EMBEDA · EVENITY · Enbrel · Erivedge · FORTEO · GenVisc 850 · HADLIMA · HUMIRA · HYRIMOZ · Humira · IDACIO · INFLECTRA · KEVZARA · KRYSTEXXA · LUPKYNIS · LYRICA · Morphabond ER · Movantik · NALOCET · OFEV · ORENCIA · Otezla · Otrexup · PROLATE · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · SYNVISC-ONE · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tymlos · Uloric · VIMOVO · XELJANZ · Zilretta · Zipsor
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $505 per 100 Medicare services performed
Looking for a rheumatology in Longview?
Compare rheumatologys in the Longview area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
3
Per 100K population
2.4
County median income
$64,809
Nearest hospital
CHRISTUS GOOD SHEPHERD MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Kamali is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (low-engagement, top 13%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Kamali experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Kamali performed 3,600 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kamali receive payments from pharmaceutical companies?
Yes. Dr. Kamali received a total of $35,771 from 43 companies across 1,672 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kamali's costs compare to other rheumatologys in Longview?
Dr. Kamali's average Medicare payment per service is $37. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kamali) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →